Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 5Thoracic 4Head & Neck 3Genitourinary 2Sarcoma 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 2Insulin Resistance 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Pioglitazone × Genitourinary × Clear all
NCT04995978 2023-06-23

Insulin Resistance and Androgen Deprivation Therapy

St. Louis University

Phase 2 Withdrawn
Genitourinary

Insulin Resistance, Prostatic Neoplasms

NCT00427999 2016-11-21

INV342

Novartis

Phase 2 Completed
67 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡